HPRA Drug Safety Newsletter 67th Edition

Download: hpra-drug-safety-newsletter-edition-67.pdf 442 KB

In this Edition

  • Bisphosphonates and denosumab: minimising the risk of osteonecrosis of the jaw (ONJ).
  • Risk of severe allergic reactions with ambroxol and bromhexine-containing medicines
    considered small.
  • New restriction for hydroxyzine-containing medicines to further minimise the known risk of QT prolongation.
  • The Importance of Product Information for Medicines.
  • Direct Healthcare Professional Communications published on the HPRA website since the last Drug Safety Newsletter.

« Back